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ESTIMATING FUTURE HEPATITIS B VIRUS (HBV) DISEASE BURDEN IN THE UNITED STATES USING A DISEASE SIMULATION MODEL
Bristol-Myers Squibb, Wallingford, CT, USA OBJECTIVE: Chronic HBV is a serious infection for which few therapeutic options exist. The CDC estimates that 1.25 million Americans are chronically infected. We estimated the burden of disease in the United States from chronic HBV and its complications such as cirrhosis and hepatocellular carcinoma (HCC) using a disease simulation model. METHODS: We analyzed US data from the NHANES III survey to derive HBsAg prevalence estimates for the age groups 20-29, 30-39, 40-49, 50-59, 60+ . Using US census data from 1991, we estimated the number of HBsAg carriers in the US in each age group.
A Markov model with eight health states (seroconversion; chronic HBV; compensated cirrhosis; decompensated cirrhosis; HCC; transplant year 1; transplant year 2; death) was used to estimate disease burden from 2002-2012. Model simulation started from 1991; all subjects were started from the chronic HBV state; cycle length was one year; subjects could move between health states annually. Transition probabilities were derived from literature. Costs were derived from a claims database analysis (Pharmetrics) and literature. RESULTS: We estimated that 653,101 people had chronic HBV infection in 1991. These formed the base population for our analysis. We estimated that from 2002-2012, there will be 133,661 cirrhosis cases; 41,101 HCC cases; 6653 liver transplants; 133,722 deaths attributable to chronic HBV infection. The total direct medical costs for these cases was estimated at $9.4B over the same time frame. CONCLU-SIONS:
The results of this analysis shows that HBV infection is a significant burden on the US healthcare system. These results are probably an underestimation of the true burden given that our estimated patient population was half of the CDC estimate and incident cases are not accounted for. The availability of an effective antiviral agent capable of modifying the disease progression would decrease this economic burden to society. 
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COST-SAVINGS OF AN IV TO PO ACYCLOVIR SWITCH IN A STANDARDIZED HSV PROPHYLAXIS PROTOCOL ON A BMT UNIT
OBJECTIVES:
The objectives of this study are to examine the clinical efficacy of using an oral (PO) acyclovir prophylactic herpes (HSV) protocol before a bone marrow transplant (BMT) versus the intravenous (IV) formulation of acyclovir, as well as the cost-savings that the oral formulation has relative to the intravenous. METHODS: Two retrospective cohorts were examined on the UCSF Medical Center Adult BMT/Leukemia Service. The first cohort consisted of 31 patients on the service for either a BMT or Peripheral Stem Cell Transplant (PSCT) in 1996. These patients were started on an IV acyclovir prophylactic protocol. The second cohort consisted of 41 patients on the same service for either a BMT or PSCT in 2001. These patients were started on an oral acyclovir prophylactic protocol. The two main outcome variables include cost per day of acyclovir treatment/prophylaxis and percentage stay on IV acyclovir. Further analyses conducted include subgroup analysis, sensitivity analysis, principal components analysis, linear regression, and an exploratory analysis. RESULTS: This study found that the oral protocol has similar clinical efficacy (2 infection in the PO group and 0 in the IV group) to the IV formu-
